Neurogenomics Market Size, Share & Growth Forecast 2031
Meticulous Research®—a
leading global market research company, published a research report
titled ‘Neurogenomics Market—Global Opportunity Analysis &
Industry Forecast to 2031’. According to this latest publication, the
neurogenomics market is expected to reach $4.68
Billion by 2031, at a CAGR of 16.6% from 2024 to 2031.
The growth of the
neurogenomics market is driven by the declining costs of sequencing, the
increasing prevalence of neurological disorders, the growing utilization of
advanced sequencing technologies in disease diagnostics & precision
medicine, increasing pharmaceutical R&D expenditures, improvements in
regulatory & reimbursement scenarios for gene sequencing, rising healthcare
expenditures, increasing funding for research activities, the growing need for
the early detection & prevention of neurological disorders, technological
advancements in neurogenomics products, and government initiatives promoting
the use of sequencing in clinical & research applications. However, the
high prices of neurogenomics products, the low chances of identifying positive actionable
mutations for precision medicine, and ethical & legal issues related to
sequencing-based diagnosis are factors restraining the growth of this market.
Furthermore, the
increasing adoption of targeted therapies, emerging economies, and rising
awareness regarding neurological disorders are expected to generate growth
opportunities for market stakeholders. However, the dynamic regulatory
landscape, the limited expertise & sequencing capabilities of small &
medium-sized laboratories, the shortage of sequencing professionals, and the
high capital investments required for sequencing setups are major challenges
impacting the growth of the neurogenomics market.
Key Players
The neurogenomics
market is moderately competitive due to the presence of many large and
small-sized regional and local players. The key players operating in the
neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc.
(U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands),
Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of
California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore
Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China). The neurogenomics
market is segmented based on offering, application, end user, and geography.
Among the offerings
studied in this report, the
next-generation sequencing (NGS) segment is anticipated to hold the dominant
position, with a share of 63.9% of the market in 2024. The
significant prevalence of neurological disorders, increasing healthcare costs,
and extensive initiatives aimed at enhancing diagnostic and treatment methods
through next-generation sequencing (NGS) are key factors driving the segment's
dominance in the neurogenomics market.
Among the
applications studied in this report, the research applications segment is anticipated to hold the dominant
position, with a share of 61.6% of the market in 2024. The
swift integration of advanced solutions such as next-generation sequencing
(NGS), PCR, and microarrays in academic and research institutions, substantial
investments in genomics research, and the increasing demand for personalized
medicine are driving the segment's dominance in the neurogenomics market.
Among the end users
studied in this report, the
pharmaceutical & biotechnology companies segment is anticipated to hold the
dominant position, with a share of 44.6% of the market in
2024. Elevated R&D expenditures by pharmaceutical and biotechnology
companies, which facilitate the adoption of advanced solutions such as
next-generation sequencing, microarrays, and PCR technologies, along with the
high incidence of neurological disorders, are key factors contributing to the
dominance in the neurogenomics market.
Among the
geographies studied in this report, North America is anticipated to hold the dominant position, with a
share of 47.2% of the market in 2024. The growth of this
market can be primarily attributed to rising R&D expenditures in the
pharmaceutical and biotechnology sector, the presence of major market players
in the region, supportive government initiatives for genomics research,
expanding applications of sequencing-based research, the increasing prevalence
of neurological diseases, and a favorable reimbursement landscape.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6019
Key Questions
Answered in the Report:
- What is the revenue generated from the
neurogenomics market globally, based on offering, application, and end
user?
- At what rate is the demand for
neurogenomics solutions projected to grow globally for the next five to
seven years?
- What are the historical market size and
growth rate for the neurogenomics market?
- What are the major factors impacting the
growth of this market?
- What are the major opportunities for
existing players and new entrants in the market?
- Which offering, application, and end-user
segments are expected to create major traction for the players in this
market?
- Who are the major players in the
neurogenomics market? What are their specific product offerings in this
market?
- What are the recent developments in the
neurogenomics market? What are the impacts of these strategic
developments?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment